Drug Profile
ETC 1922159
Alternative Names: ETC-159; ETC1922159Latest Information Update: 06 Jul 2023
Price :
$50
*
At a glance
- Originator D3 (Drug Product and Development), Biomedical Sciences Institute
- Developer D3 (Drug Discovery & Development), Biomedical Sciences Institute
- Class Antineoplastics
- Mechanism of Action PORCN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Jul 2023 ETC 1922159 is still in phase I trials for Solid-tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02521844)
- 02 Jun 2023 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (PO)